FEMALE FEBRILE SEIZURE PANEL

Female Febrile Seizure Panel contains the following tests– SCN1A, SCN2A, SCN1A-DEL/DUP, SCN1B, GABRG2, GABRD and PCDH19

Test Order Code	FFSP
CPT Codes	83891 x 1, 83892 x 1, 83896 x 26, 83898 x 62, 83900 x 1, 83901 x 24, 83904 x 62, 83909 x 63, 83912 x 1
Indications For Testing	For female infants and children; Indicators include seizures, including typical febrile seizures or atypical febrile seizures in which seizures occur after six years of age, and afebrile tonic-clonic, myoclonic, absence, or atonic seizures.
Turn Around Time	Three weeks. Expedited analysis is available upon request for an additional charge.
Specimen Requirements	Ship one of the following: Saliva You must order either the DNA Specimen Collection Kit – Sponge Swab (Part Number 443006) or the DNA Specimen Collection Kit – Saliva Tube (Part Number 443007) from Transgenomic to send a saliva sample. Follow the directions in the kit for specific saliva collection requirements. Peripheral Blood A full 4 ml blood sample in the 4 ml Lavender-top (EDTA) tube provided in the DNA Specimen Collection Kit (Part Number 443002) is required. Keep the sample at ambient temperature and ship by overnight courier to the test laboratory.
Specimen Kits	DNA Specimen Collection Kits can be obtained from Transgenomic Labs.
Shipping and Contact Information	Transgenomic Labs Five Science Park, New Haven, CT 06511 USA Phone:1.877.274.9432 Fax: 203.786.3418 E-mail: labservice@transgenomiclabs.com
Test Submission and Patient Consent Form	Test Requisition and Patient Consent Form Due to the unique nature of genetic testing, patients should receive pre-test and post-test counseling. Informed consent is recommended.
Test Methodology	See individual tests.

Note: The performance characteristics of this test were validated by Transgenomic Labs. The U.S. Food and Drug Administration (FDA) has not approved this test. However, FDA approval is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. Transgenomic Labs is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.